[Acute pneumonia treatment with a new antibiotic (tobramycin) (author's transl)]

Area of Science:

• Pharmacology
• Infectious Diseases
• Pulmonology

Background:

• Acute infectious pulmonary disease requires effective antibiotic treatment.
• Gram-negative bacteria are common pathogens in severe pneumonia.
• Aminoglycoside antibiotics are a key therapeutic class.

Observation:

• Tobramycin was administered to 30 patients with acute infectious pulmonary disease (types I, II, III).
• 29 patients had type II or III disease, indicating severe or complex cases.
• Diagnosis was confirmed using clinical, laboratory, radiological, and microbiological criteria.

Findings:

• Tobramycin achieved a 89.3% (25/28) therapeutic success rate in evaluable patients.
• Gram-negative bacteria, particularly Klebsiella-Enterobacter, were predominant pathogens.
• The Minimum Inhibitory Concentration (MIC) for isolated pathogens was low (<1.0 µg/mL) in 26 cases.
• Adverse reactions occurred in 13 patients, with 9 showing only laboratory changes.

Implications:

• Tobramycin demonstrates significant efficacy in treating acute infectious pulmonary disease.
• Its effectiveness against key gram-negative pathogens supports its use.
• The favorable safety profile, with mostly laboratory alterations, is promising.